Issue 76, 2021

Enantioselective total synthesis of (+)-rubrobramide, (+)-talaramide A, and (−)-berkeleyamide D by a skeletal diversification strategy

Abstract

A unified synthesis of (+)-rubrobramide, (+)-talaramide A, and (−)-berkeleyamide D was achieved from the vinylogous esters by a skeletal diversification strategy based on regioselective 5-exo or 6-endo cyclization. This report describes the first enantioselective total synthesis of (+)-rubrobramide and (+)-talaramide A. Additionally, synthetic spirocyclic lactam compounds, including (−)-berkeleyamide D, showed moderate inhibitory activity against amyloid-β aggregation for the potential treatment of Alzheimer's disease.

Graphical abstract: Enantioselective total synthesis of (+)-rubrobramide, (+)-talaramide A, and (−)-berkeleyamide D by a skeletal diversification strategy

Supplementary files

Article information

Article type
Communication
Submitted
05 Aug 2021
Accepted
30 Aug 2021
First published
30 Aug 2021

Chem. Commun., 2021,57, 9780-9783

Enantioselective total synthesis of (+)-rubrobramide, (+)-talaramide A, and (−)-berkeleyamide D by a skeletal diversification strategy

K. Tanaka, K. Kobayashi and H. Kogen, Chem. Commun., 2021, 57, 9780 DOI: 10.1039/D1CC04290D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements